Miragen Therapeutics, Inc. appears to be an “attractive investment opportunity,” with its microRNA pipeline demonstrating early clinical efficacy, the presence of near-term catalysts and the potential for “multi-billion dollars in product sales,” Wedbush’s Liana Moussatos said in a report.Moussatos initiated coverage of miRagen Therapeutics with an Outperform rating and a price target of $19.Promising Lead Candidates“Using established microRNA disease targets and pathways, each program is progressively de-risked early in development,” Moussatos wrote. miRagen Therapeutics currently has two lead programs, namely MRG- 106, a miR-155 inhibitor for hematologic malignancies, and MRG-201, a miR-29 mimetic for fibrotic diseases.“Both programs have established clinical proof of mechanism, demonstrated single dose target engagement, initial efficacy and an acceptable safety and tolerability profile in our view,” the analyst commented.Source